Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(6):489-490; doi:10.1093/jnci/djk100
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Etzioni, R. D.
Right arrow Articles by Thompson, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Etzioni, R. D.
Right arrow Articles by Thompson, I. M.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

CORRESPONDENCE

Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability

Ruth D. Etzioni, Donna P. Ankerst, Ian M. Thompson

Affiliations of authors: Fred Hutchinson Cancer Research Center, Program in Biostatistics, Seattle, WA (RDE); Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX (DPA, IMT)

Correspondence to: Ian M. Thompson, MD, Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl, San Antonio, TX 78229-3900 (e-mail: thompsoni@uthscsa.edu).

The first 10% of the full text of this article appears below.

Carter et al. (1) suggest that prostate-specific antigen velocity (PSAV, change in PSA over a defined interval) is a useful measure to detect life-threatening prostate cancer during a window of curability 10–15 years before diagnosis. They recommend that a PSAV greater than 0.35 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

Response: Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability
H. Ballentine Carter, Luigi Ferrucci, Anna Kettermann, Patricia Landis, James Wright, Jonathan I. Epstein, Bruce J. Trock, and E. Jeffrey Metter
J Natl Cancer Inst 2007 99: 490. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
H. B. Carter, L. Ferrucci, A. Kettermann, P. Landis, J. Wright, J. I. Epstein, B. J. Trock, and E. J. Metter
Response: Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability
J Natl Cancer Inst, March 21, 2007; 99(6): 490 - 490.
[Full Text] [PDF]